StockData
NovaBridge Biosciences logo

NovaBridge Biosciences (NBP) shareholders

NBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 7, 2026Score 0/30
$0.82+0.03 (+3.89%)

Close on Nov 17, 2026Market cap $94.88MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
9.3%
25M of 265M shares
Institutional holders
49
13 new, 11 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
1 buys · 7 sales
Net bought $423.03K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Everest Medicines Limited42,524,71616.10%13D (active)Aug 5, 2025
Wei Fu
Joint filing with C-Bridge Capital GP, Ltd. (8.80%), C-Bridge Healthcare Fund II, L.P. (5.30%) and 1 more
30,499,70911.50%13D (active) amendmentJan 29, 2026
Jingwu Zhang Zang10,454,9375.60%13G (passive) amendmentDec 31, 2023
T Investment Limited8,172,0229.89%13D (active)Nov 22, 2023

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of NBPValueChange% of portfolio
Hhlr Advisors, Ltd.5,980,5682.25%$11.66M–1.40%
Morgan Stanley3,653,2281.38%$7.12M−184,9700.00%
AIHC Capital Management Ltd2,878,0331.08%$5.61M+615,1005.38%
Siren, L.L.C.2,004,7390.76%$3.91M−995,2610.08%
Marshall Wace, Llp1,231,9460.46%$2.40MNew0.00%
Candriam S.C.A.1,132,5630.43%$2.21M–0.01%
Adage Capital Partners Gp, L.L.C.1,000,0000.38%$1.95M–0.00%
Two Sigma Investments, LP851,3480.32%$1.66MNew0.00%
Renaissance Technologies LLC758,2260.29%$1.48M+485,8140.00%
BlackRock, Inc.686,2080.26%$1.34M+58,7120.00%
Citadel Advisors LLC622,8310.23%$1.21M+456,2150.00%
E Fund Management Co., Ltd.589,0200.22%$1.15MNew0.03%
Exome Asset Management LLC576,9600.22%$1.13M–0.69%
State Street Corp360,3760.14%$702.73K−9,7310.00%
Woodline Partners LP350,0000.13%$682.50K−350,0000.00%
Fiera Capital Corp315,6810.12%$615.58K–0.00%
UBS Group AG301,7800.11%$588.47K+238,2390.00%
Barclays PLC279,0190.11%$544.09K−20,2800.00%
Taikang Asset Management (Hong Kong) Co Ltd170,9310.06%$333.32K–0.03%
Goldman Sachs Group Inc161,3210.06%$314.58K+48,8580.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 20264925M9.3%13 / 1311 / 115M4M
Q1 20264829M11.0%9 / 1415 / 183M7M
Q4 20255733M12.5%21 / 1612 / 59M5M
Q3 20254230M11.2%21 / 106 / 1121M1M
Q2 2025329M3.5%10 / 58 / 71M1M
Q1 2025299M3.4%5 / 55 / 31M4M
Q4 20242812M4.5%7 / 36 / 74M7M
Q3 20242814M5.3%4 / 56 / 130M1M
Q2 20243815M5.7%3 / 419 / 44M1M
Q1 20243912M4.6%6 / 119 / 112M3M
Q4 20234413M4.8%11 / 1114 / 132M4M
Q3 20234715M5.7%12 / 914 / 122M5M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

17 funds held NBP in Q1 2026, 85% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of NBPValue% of fundAs of
iShares Biotechnology ETF591,3810.22%$1.15M0.01%Jun 30, 2026
State Street(R) SPDR(R) Portfolio Emerging Markets ETF297,8470.11%$580.80K0.00%Jun 30, 2026
Fidelity Nasdaq Composite Index Fund68,8490.03%$126.68K0.00%May 31, 2026
State Street(R) SPDR(R) S&P(R) Emerging Markets Small Cap ETF48,3190.02%$94.22K0.01%Jun 30, 2026
World ex U.S. Core Equity Portfolio26,3300.01%$42.13K0.00%Jul 31, 2026
Invesco NASDAQ Future Gen 200 ETF23,4270.01%$43.11K0.23%May 31, 2026
Emerging Markets Core Equity 2 Portfolio20,0350.01%$32.06K0.00%Jul 31, 2026
Emerging Markets Social Core Equity Portfolio15,1300.01%$24.21K0.00%Jul 31, 2026
State Street(R) SPDR(R) S&P(R) China ETF14,2100.01%$27.71K0.01%Jun 30, 2026
Emerging Markets Sustainability Core 1 Portfolio9,3060.00%$14.89K0.00%Jul 31, 2026
Invesco Nasdaq Biotechnology ETF5,9250.00%$10.90K0.02%May 31, 2026
Blackstone Alternative Multi-Strategy Fund5,1000.00%$9.95K0.00%Jun 30, 2026
ProShares Ultra Nasdaq Biotechnology4,1510.00%$7.64K0.01%May 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Srishti GuptaChief Executive Officer, Director––Jul 8, 2026
Xi-Yong FuSee Remarks, Director59,8230.02%Mar 18, 2026
Charles SilbersteinChief Financial Officer––Nov 2, 2026
Phillip Andrew DennisChief Medical Officer173,4270.07%Sep 21, 2026
Sean Wuxiong CaoChief Bus. Development Officer266,4670.10%Sep 11, 2026
Cong Claire XuEVP, Clinical Development304,2010.11%Sep 1, 2026
Mark Arnold HaglerChief Commercial Officer230,0000.09%Jul 10, 2026
Liwei Lorraine LinGeneral Counsel––Jul 10, 2026
Denny Hsueh Wen ChuSee Remarks––Mar 24, 2026
Xiaofan Neo ZhangChief Investment Officer874,0000.33%Mar 18, 2026
Ming Kyler LeiChief Financial Officer––Mar 18, 2026
Adeline Yi ZhangGlobal Controller––Mar 18, 2026
Joanna Xuqiong WuSee Remarks5,7500.00%Mar 18, 2026
Ian Ying WooDirector13,2710.01%Oct 19, 2026
Martin William DewhurstDirector––Sep 10, 2026
Robert A. LenzDirector17,2180.01%Aug 25, 2026
Wei FuDirector30,499,69911.49%Jun 30, 2026
Conor Chia-hung YangDirector––Apr 1, 2026
Chun Kwok Alan AuDirector––Mar 18, 2026
Xin LiuDirector––Mar 18, 2026
Emmett CunninghamDirector––Mar 18, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Ian Ying Woo
Director
Oct 15, 2026Option exercise+13,271––13,271
Phillip Andrew Dennis
Chief Medical Officer
Sep 18, 2026Sale−8,209$0.71$5.83K173,427
Phillip Andrew Dennis
Chief Medical Officer
Sep 17, 2026Option exercise+23,695––181,636
Sean Wuxiong Cao
Chief Bus. Development Officer
Sep 9, 2026Sale−107,978$0.74$79.90K266,467
Sean Wuxiong Cao
Chief Bus. Development Officer
Sep 3, 2026Option exercise+235,136––270,209
Sean Wuxiong Cao
Chief Bus. Development Officer
Sep 3, 2026Option exercise+104,236––374,445
Cong Claire Xu
EVP, Clinical Development
Aug 31, 2026Sale−3,282$0.79$2.59K304,201
Cong Claire Xu
EVP, Clinical Development
Aug 30, 2026Option exercise+9,382––307,483
Robert A. Lenz
Director
Aug 22, 2026Option exercise+17,218––17,218
Cong Claire Xu
SVP, Clinical Development
Jul 6, 2026Sale−4,485$0.89$3.99K298,101
Cong Claire Xu
SVP, Clinical Development
Jul 4, 2026Option exercise+12,432––302,586
Phillip Andrew Dennis
Chief Medical Officer
Jun 18, 2026Sale−8,494$0.66$5.61K157,941
Phillip Andrew Dennis
Chief Medical Officer
Jun 17, 2026Option exercise+23,695––166,435
Cong Claire Xu
SVP, Clinical Development
Jun 1, 2026Sale−3,494$3.94$13.77K290,154
Cong Claire Xu
SVP, Clinical Development
May 30, 2026Option exercise+9,382––293,648
Sean Wuxiong Cao
See Remarks, Director
May 14, 2026Sale−21,399$1.99$42.58K35,073
Mark Arnold Hagler
See Remarks
Apr 24, 2026Buy+230,000$2.51$577.30K230,000

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
4M shares short
Days to cover
6.9
At 1M shares a day
Change since last report
-3.3%
From 4M shares
Short volume, 20 days
49.7%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of NovaBridge Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,698,259 shares on Sep 28, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Phillip Andrew Dennis
Chief Medical Officer
Sep 18, 20263,569$5.80KSep 18, 2026Restricted Stock Vesting
Sean Wuxiong Cao
Officer, CHIEF BUSINESS DEVELOPMENT OFFICER
Sep 9, 202646,947$79.38KSep 9, 2026RESTRICTED STOCK UNITS VESTING
Sean Wuxiong Cao
Officer, CHIEF BUSINESS DEVELOPMENT OFFICER
May 14, 20269,304$18.53KMay 14, 2026RESTRICTED SHARE UNITS VESTING
Phillip Andrew Dennis
Chief Medical Officer
Mar 18, 20263,638$10.15KMar 18, 2026Restricted Stock units Vesting
Skelton Joseph W.
Officer, FORMER CFO
Jan 2, 2026120,000$519.60KJan 2, 2026STOCK OPTION EXERCISE AND SALE PURSUANT TO 10B51 PLAN
Phillip Andrew Dennis
CHIEF MEDICAL OFFICER
Dec 18, 20253,431$14.50KDec 18, 2025Restricted Stock Units Vesting
Kannan Raj
Officer, CEO
Jul 26, 202450,000$69.50KJul 26, 2024ACQUIRED STOCK UNDER COMPANY SHARE INCENTIVE PLAN
Kannan Raj
Officer, CEO
Jul 17, 2024300,000$489.00KJul 17, 2024ACQUIRED STOCK UNDER COMPANY SHARE INCENTIVE PLAN
Feng Gigi Qi
Officer, CHIEF COMMUNICATIONS OFFICER
Mar 15, 2024150$270Mar 15, 2024ACQUIRED STOCK UNDER THE COMPANY SHARE INCENTIVE PLAN
Tang Weimin
Officer, CHIEF BUSINESS OFFICER
Feb 8, 202420,000$40.00KFeb 8, 2024ACQUIRED STOCK UNDER COMPANY SHARE INCENTIVE PLAN
Zhu Andrew
Officer, PRESIDENT AND ACTING CEO
Jan 5, 202430,000$63.60KJan 5, 2024ACQUIRED STOCK UNDER COMPANY SHARE INCENTIVE PLAN
Li Richard Cheng
Officer, CHIEF LEGAL OFFICER
Dec 29, 202385,700$156.83KDec 29, 2023ACQUIRED STOCK NDER COMPANY SHARE INCENTIVE PLAN
Feng Gigi Qi
Officer, CHIEF COMMUNICATION OFFICER
Dec 26, 202320,000$31.00KDec 26, 2023ACQUIRED STOCK NDER COMPANY SHARE INCENTIVE PLAN
Li Richard Cheng
Officer, CHIEF LEGAL OFFICER
Nov 16, 202385,700$147.40KNov 16, 2023ACQUIRED STOCK UNDER COMPANY SHARE INCENTIVE PLAN
Everest Medicines Ltd
10% Stockholder
Oct 10, 20236,078,555$4.47MOct 24, 2023Private placement

See a number that looks wrong?